[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519561":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":52,"collaborators":26,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":26,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":26,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":34,"whyStopped":26,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tirofiban group","ACTIVE_COMPARATOR","Tirofiban infused with 0.4μg\u002Fkg\u002Fmin for 30min and 0.1μg\u002Fkg\u002Fmin until 24h after IVT",[13],"Drug: Tirofiban",{"label":15,"type":16,"description":17,"interventionNames":18},"Tirofiban simulant group","PLACEBO_COMPARATOR","Tirofiban simulant infused with 0.4μg\u002Fkg\u002Fmin for 30min and 0.1μg\u002Fkg\u002Fmin until 24h after IVT",[19],"Drug: Tirofiban simulant",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tirofiban","Tirofiban is a selective glycoproteinⅡb\u002FⅢa receptor inhibitor, which inhibits platelet aggregation and thrombi formation",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Tirofiban simulant","Tirofiban simulant is placebo packed the same style as tirofiban",[15],[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"The first hospital of Jilin University","RECRUITING","Changchun","Jilin","130000","China","CN",{"type":41,"coordinates":42},"Point",[43,44],125.32278,43.88,{"lat":44,"lon":43},[47],{"name":48,"role":49,"phone":50,"phoneExt":26,"email":51},"Yi Yang, MD, PhD","CONTACT","13756661217","doctoryangyi@163.com",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Yi Yang","Associated Dean of First Hospital of Jilin University","100519561","early-tirofiban-administration-after-intravenous-thrombolysis-in-acute-ischemic-stroke-100519561",false,"NCT06045156","Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke","Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n1. Age≥18 years old;\n2. Clinically diagnosed as acute ischemic stroke and received standard dose (0.25mg\u002Fkg) of tenecteplase IVT within 4.5 hours of onset;\n3. Total National Institute of Health stroke scale (NIHSS)≥4 or single limb motor item score≥2, and total NIHSS≤15 after IVT;\n4. Tirofiban or placebo treatment can be initiated within 6h after IVT;\n5. mRS score before onset≤ 1;\n6. Intracranial hemorrhage is ruled out by CT head after IVT;\n\nExclusion Criteria:\n\n1. Received or plan to undergo bridge therapy;\n2. Large area of infarct indicated by radiological imaging(≥1\u002F3 of middle cerebral artery supply area);\n3. Atrial fibrillation or suspected cardiac embolism;\n4. Accompanied by epileptic seizures;\n5. Using antiplatelet, anticoagulant or fibrinolytic agents within 24h before recruitment;\n6. Active bleeding or tendency to bleed after receipt of intravenous thrombolysis;\n7. Digestive system bleeding, urinary system bleeding, hemorrhagic retinopathy or other systemic bleeding events within 1 year;\n8. Severe renal or liver insufficiency; ALT or AST\\>3 times of the upper limit of normal value or above; creatinine clearance rate\\\u003C30 mL\u002Fmin, creatinine\\>200μmol\u002FL；\n9. Life expectancy less than 3 months;\n10. Pregnant or lactating women;\n11. Known allergy to tirofiban;\n12. Being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial.;\n13. Patients who are unwilling to be followed up or likely to have poor treatment compliance;\n14. Other situations that the researcher deems unsuitable for inclusion in the study.","ALL","18 Years",{"count":66,"type":67},1084,"ESTIMATED","INTERVENTIONAL",[70],"NA","The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT",[73],"Acute Ischemic Stroke",[75,76,77],"acute ischemic stroke","intravenous thrombolysis","tirofiban","2025-12-22",{"date":80,"type":81},"2025-12-30","ACTUAL",{"date":83,"type":81},"2024-04-29",{"date":85,"type":67},"2026-12-30",{"name":5,"class":6},1]